

Ruxolitinib (JAKAFI) in Graft Versus Host Disease (GVHD)

Criteria for Use

October 2025

VA Pharmacy Benefits Management Services and National Formulary Committee

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

See the VA National Formulary Committee Monograph on this drug at the [PBM INTRAnet](#) site for further information.

Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive ruxolitinib.

- Active or uncontrolled infection
- Unmanageable drug-drug interaction
- End-Stage Renal Disease (CrCl < 15ml/min) not on dialysis
- Absolute Neutrophil Count (ANC) $\leq 1000/\text{mm}^3$ and/or platelet count $\leq 25,000/\text{mm}^3$ unless associated with Duffy-null Associated Neutrophil Count (DANC)
- Lactating

Inclusion Criteria

All of the following criteria must be met.

- Care provided by a VA or VA Community Care hematology provider
- Eastern Cooperative Oncology Group performance status 0-2
- Steroid-refractory (or dependent) acute Graft Versus Host Disease (GVHD) following allogeneic stem cell transplant or steroid-refractory chronic GVHD after ≥ 1 line of therapy with progression, lack of response or steroid-intolerance

Additional Inclusion Criteria

- For females who are breastfeeding: Manufacturer recommends discontinuing breastfeeding during treatment with ruxolitinib and for 2 weeks after stopping treatment.

Other Justification
